Methotrexate for the Treatment of Recalcitrant Primary Localized Cutaneous Amyloidosis: A Case Series | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Methotrexate for the Treatment of Recalcitrant Primary Localized Cutaneous Amyloidosis: A Case Series

key information

source: Acta Dermato-Venereologica

year: 2018

authors: Stull CM, Tey HL, Yosipovitch G

summary/abstract:

Primary localized cutaneous amyloidosis (PLCA) is characterized by deposition of keratinocyte-derived amyloid within the papillary dermis. PLCA often presents with intensely pruritic, waxy papules that coalesce into plaques on the extensor surfaces of the extremities. PLCA is most common in Asians and South Americans, and has been associated with atopic dermatitis.
 
PLCA poses a therapeutic challenge. Various treatment methods have been employed, but evidence in the form of randomized controlled trials is lacking. Topical therapies for PLCA include high potency steroids, calcipotriene, and menthol. Systemic therapies include acitretin, cyclophosphamide and cyclosporine. Additionally, the use of phototherapy and laser therapy has been reported. Despite the array of available treatments, PLCA often exhibits limited response, with frequent recurrence. Herein, we describe two cases of PLCA successfully treated with methotrexate (MTX).
 
organization: Rush University, USA

DOI: 10.2340/00015555-2991

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close